Age-neutral guidelines for the primary prevention of cardiovascular disease

Journal of Clinical Hypertension

Volumn 11, Issue 11, 2009, Pages 644-645

  Kostis, William J ^a   Kostis, John B ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; GLUCOSE;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; NOTE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR;

ADULT; AGE FACTORS; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 70449377075     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00162.x     Document Type: Note

References (19)

1. Cutler JA, Sorlie PD, Wolz M. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008, 52(5):818-827.
2. Hyre AD, Muntner P, Menke A. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007, 17(7):548-555.
3. Prevention of Cardiovascular Disease. Guidelines for Assessment and Management of Total Cardiovascular Risk 2007, WHO, Geneva, World Health Organization
4. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007, 28(19):2375-2414. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
5. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001, 285:2486-2497.
6. Ridker PM, Buring JE, Rifai N. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007, 297(6):611-619.
7. Kostis JB. A new approach to primary prevention of cardiovascular disease. Am J Med 2007, 120:746-747.
8. Mosca L, Banka CL, Benjamin EJ. For the Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007, 115:1481-1501.
9. Kostis JB. Disputation of the use of age in determining the need for treatment of hypercholesterolemia and hypertension. J Clin Hypertens 2006, 8(7):519-520.
10. Brown MS, Goldstein JL. Lowering LDL - not only how low, but how long?. Science 2006, 311:1721-1723.
11. Jackson PR. The influence of absolute cardiovascular risk, patient utilities and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 2003, 21(9):1631-1634.
12. Pitt B. Generic drugs in cardiology: will they reduce health care costs?. J Am Coll Cardiol 2004, 44(1):10-13.
13. Baron J, Messick DM, Tenbrunsel AE. Do no harm. Codes of Conduct: Behavioral Research into Business Ethics 1996, 197-213. In, eds, New York, NY, Russell Sage Foundation
14. Ridker PM, Danielson E, Fonseca FA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207. for the, JUPITER Study Group
15. McKenney JM, Davidson MH, Jacobson TA. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97(8A):89C-94C. for the, National Lipid Association Statin Safety Assessment Task Force
16. Krumholz HM. Guideline recommendations and results: the importance of the linkage. Ann Intern Med 2007, 147:342-343.
17. Burke W, Psaty BM. Personalized medicine in the era of genomics. JAMA 2007, 298(14):1682-1684.
18. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009, 373(9670):1152-1155.
19. Kraft P, Hunter DJ. Genetic risk prediction - are we there yet?. N Engl J Med 2009, 360(17):1701-1703.